ASSESS-meso: a long-term study looking at people with mesothelioma (cancer of the outer lining of the lung) that will gather information on symptoms, disease processes and factors that affect survival

A prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma that will provide a resource for future trials

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN61861764

Enrollment

700

Registered

2018-01-24

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mesothelioma (cancer of the outer lining of the lung) Cancer

Interventions

This is an observational study, with no additional intervention above usual clinical care. Participants are followed up from the point of diagnosis until death or withdrawal from the study. Data is c

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1. Histological, cytological or clinico-pathological diagnosis of mesothelioma, confirmed at MDT 2. Willing and able to comply with study follow up assessments (including at least 1 appointment at a study recruiting centre if identified at a PIC) 3. Has capacity, as defined by the 2005 Mental Capacity Act

Exclusion criteria

Exclusion criteria: 1. Age < 18 years old 2. Unable to give written informed consent 3. Declines ongoing hospital follow up

Design outcomes

Primary

Measure	Time frame
Survival is measured as time from diagnosis to death (or censored at the point of withdrawal from the study) at every study visit.	—

Secondary

Measure	Time frame
1. Disease progression, assessed on CT scans using modified RECIST criteria at baseline and every 6 months 2. Change in serum mesothelin from baseline, assessed on blood tests taken at baseline and every 3 months 3. Patient reported symptom scores for breathlessness, chest pain and sweats, measured using visual analogue scales at baseline and every 3 months. 4. Patient reported quality of life, assessed using the EQ-5D-5L questionnaire, at baseline and every 3 months. 5. Pleurodesis rates assessed using pleural catheter drainage diaries, chest x-ray and thoracic ultrasound every 3 months. Pleurodesis is defined as "less than 50ml of pleural fluid drained on 3 or more successive drainages, with no evidence of residual fluid on chest x-ray or ultrasound". 6. Health services utilisation, assessed from patient history and hospital records every 3 months. In addition data will be collected on confounding factors including: 1. Patient characteristics e.g. age, sex, presence of comorbidities, performance status - collected at baseline from patient history & medical records 2. Tumour variables e.g. histological type, disease site - collected at baseline from medical records 3. Treatment factors e.g. chemotherapy, radiotherapy, participation in clinical trials - collected at baseline and every 3 months based on patient history 7 medical records	—

Measure

Time frame

1. Disease progression, assessed on CT scans using modified RECIST criteria at baseline and every 6 months 2. Change in serum mesothelin from baseline, assessed on blood tests taken at baseline and every 3 months 3. Patient reported symptom scores for breathlessness, chest pain and sweats, measured using visual analogue scales at baseline and every 3 months. 4. Patient reported quality of life, assessed using the EQ-5D-5L questionnaire, at baseline and every 3 months. 5. Pleurodesis rates assessed using pleural catheter drainage diaries, chest x-ray and thoracic ultrasound every 3 months. Pleurodesis is defined as "less than 50ml of pleural fluid drained on 3 or more successive drainages, with no evidence of residual fluid on chest x-ray or ultrasound". 6. Health services utilisation, assessed from patient history and hospital records every 3 months. In addition data will be collected on confounding factors including: 1. Patient characteristics e.g. age, sex, presence of comorbidities, performance status - collected at baseline from patient history & medical records 2. Tumour variables e.g. histological type, disease site - collected at baseline from medical records 3. Treatment factors e.g. chemotherapy, radiotherapy, participation in clinical trials - collected at baseline and every 3 months based on patient history 7 medical records

—

Countries

England, Scotland, United Kingdom, Wales

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jul 3, 2026